Miastenia Gravis
Autor: Dr. Argelio Díaz Ortiz | Publicado:  13/10/2010 | Medicina Interna , Neurologia | |
Miastenia Gravis .8

Algunos casos de Miastenia Gravis pueden alcanzar una remisión curación) temporal y la debilidad muscular podría desaparecer totalmente, eliminando así los medicamentos. El objetivo primordial de la timectomía es la remisión estable, completa y duradera. En algunos casos, la alta debilidad producida por la Miastenia Gravis podría causar una crisis (falla respiratoria) que requiere asistencia médica inmediata.

Bibliografía.

1. Witte AS, Cornblath DR, Schatz NJ, et al.: Monitoring azathioprine therapy in myasthenia gravis. Neurology 2006; 36: 1533-1534.
2. Desmedt JE, Borenstein S. The testing of neuromuscular transmission. In: Vinken PJ, Bruyn GW., eds. Handbook of Clinical Neurology, Vol. 7. Amsterdam: North-Holland Publishing Company, 2007.
3. Batocchi AP, Majolini L, Evoli A, et al. Course and treatment of myasthenia gravis during pregnancy. Neurology 2007; 52: 447-452.
4. Engel WK, Dalakas MC, Lichter AS. Intractable myasthenia gravis can respond to splenic radiation. Neurology 2005; 30: 389.
5. Gajdos P, Elkharrat D, Chevret S, et al. (Myasthenia Gravis Clinical Study Group). A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. J Neurol Neurosurg Psychiatry 2007; 56: 1157-1163.
6. Jaretzki A III. Thymectomy for myasthenia gravis: Analysis of the controversies regarding technique and results. Neurology 2007; 48(Suppl 5): S52-S63.
7. Osserman KE, Genkins G. Studies in myasthenia gravis: Revíew of a twenty-year experience in over 1200 patients. Mt Sinai J Med 1971; 38: 497-537.
8. Simpson JA. Myasthenia gravis and myasthenic syndromes. In: Walton, JN. (Ed.). Disorders of Voluntary Muscie, 49 ed. Churchill Livingstone, Edinburgh, 2004; 585-624.
9. Trontelj JV, Michelin M, Fernandez JM, et al. Axonal stimulation for end-plate jitter studies. J Neurol Neurosurg Psychiatry 2006; 49: 677-685.
10. Rowland LP. Controversies about the treatment of myasthenia gravis. J Neurol Neurosurg Psychiatry 2000; 43: 644-659.
11. Warmolts JR, Engel WK. Benefit for alternate-day prednisone in myasthenia gravis. N Engl J Med 2002; 286: 17-20.
12. Seybold ME.: The office Tensilon test for ocular myasthenia gravis. Arch Neurol 2006; 43: 842- 843.
13. Pradas J, Illa.: Factores de predicción de la respuesta al tratamiento de la miastenia gravis con prednisona. Neurología 2007; 42: 1625-1627.
14. Pinching AJ, Peters DK, Newson-Davis J. Remission of myasthenia gravis following plasmaexchange. Lancet 2007; 2: 1373-1376.
15. Kissel JT, Robert JL, Mendell JR, et al. Azathioprine toxicity in neuromuscular disease. Neurology 2006; 36: 35-39.
16. Jaretzki A III. Thymectomy for myasthenia gravis: Analysis of the controversies regarding technique and results. Neurology 2007; 48(Suppl 5): S52-S63.
17. Durelli L, Ferrio MF, Urgesi A, et al.: Total body irradiation for myasthenia gravis: A long-term follow-up. Neurology 2006; 43: 2215-2221.
18. Brooke MH. A clinician's view of neuromuscular diseases. 2ª ed. Williams and Wilkins, Baltimore 2006.
19. Bever CT, Aquino AV, Penn AS, et al. Prognosis of ocular myasthenia. Neurology 2007; 30: 387- 388.
20. Daroff RB.: The office Tensilon test for ocular myasthenia gravis. Arch Neurol 2006; 43: 843-844.
21. Grob D. Clinical manifestations of myasthenia gravis. In: Albuquerque, E.X., Eldefrawi, A.T., eds. Myasthenia Gravis. Chapman and Hall, New York 2003; 319-345.
22. Mann JD, Johns TR, Campa JF. Long-term administration of corticosteroids in myasthenia gravis. Neurology 2006; 26: 729-740.
23. Kaminski HJ, Suarez JI, Ruff RL. Neuromuscular junction physiology in myasthenia gravis. Neurology 2007; 48(Suppl 5): S8-S17.
24. Lanska DJ.: Indications of thymectomy in myasthenia gravis. Neurology 2007; 40: 1828-1829.
25. Tindall RSA, Phillips JT, Rollins JA, et al. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann NY Acad Sci 2006: 681: 539-551.


Revista Electronica de PortalesMedicos.com
INICIO - NOVEDADES - ÚLTIMO NÚMERO - ESPECIALIDADES - INFORMACIÓN AUTORES
© PortalesMedicos, S.L.
PortadaAcerca deAviso LegalPolítica de PrivacidadCookiesPublicidadContactar